|
 |
MacugenThis page contains recent news articles, when available, and an overview of Macugen but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Additionally, GILD receives royalties for Tamiflu (marketed by Hoffmann-La Roche) for the treatment and prevention of influenza A and B, and Macugen ... Seeking Alpha (blog) Ophthotech Raises $30 Million in Series B Financing - Dec 15, 2009 Our investment decision was driven by the quality of the pipeline and the experience of the management team, who successfully developed Macugen® into the ... PR Newswire (press release) Diabetici by nemÄ›li zapomÃnat na pravidelné prohlÃdky u oÄ?nÃho lékaÅ™e - Dec 22, 2009 Co vÅ¡echno to způsobÃ, je loterie. jeden z modernÃch léků (Macugen, Avastim, Lucentis) potlaÄ?ujÃcà růstový hormon. Ten rizikovou tvorbu nových cév vyvolává. ... Novinky Study on the Investigational Use of Macugen in Patients With Diabetic ... - Oct 24, 2009 ..."This limited study suggests that Macugen may have the potential to produce marked and rapid short-term regression of diabetic neovascularization. ... PR-USA.net (press release) Britain's National Health Service Denied Sight-Saving Medicine to Its Own Employee - Nov 13, 2009 Though two such effective drugs, Macugen and Lucentis, are licensed for general NHS use, the Dorset Trust, which controls funding prescriptions, ... National Center for Public Policy Research Zacks Analyst Blog Highlights: Enzon, Merck, OSI Pharmaceuticals, Pfizer and ... - Nov 11, 2009 ...marketed by Merck (MRK - Analyst Report); Macugen, marketed by OSI Pharmaceuticals (OSIP - Analyst Report) and Pfizer (PFE - Analyst Report); Pegasys, ... Zacks.com Enzon Inc. Reports Operating Results (10-Q) - Nov 3, 2009 In addition Enzon also receives royalties on sales of PEG-INTRON marketed by Schering-Plough Corporation and MACUGEN marketed by OSI Pharmaceuticals and ... GuruFocus.com Pfizer's Handa is new MD of Wyeth India - Oct 26, 2009 ...on an income of Rs 1019.76 crore for FY 07. Pfizer has launched five patented products in India since 2005 — Vfend, Viagra, Lyrica, Caduet and Macugen. Financial Express Ä?iá»?u trị cáºn thị: Những phÆ°Æ¡ng pháp hiệu quả - Oct 26, 2009 ...tiêm ná»™i nhãn Macugen hay gần đây là Bevacizumab, Ä‘iá»?u trị khá hiệu quả vá»›i các dạng tân mạch dÆ°á»›i võng mạc do thoái hóa hoà ng Ä‘iểm, cáºn thị bệnh ly. ... Báo Hoà Bình European Panel Supports Macugen - Sep 16, 2005 A European regulatory committee is recommending approval of Macugen, a treatment for an eye disease called wet age-related macular degeneration, ... TheStreet.com - TheStreet.com (subscription) OSI Narrows Macugen Outlook | Biotech/Pharmaceuticals | Financial … - Jan 11, 2006 By Althea Chang 01/11/06 - 01:41 PM EST. OSI Pharmaceuticals (OSIP Quote) narrowed the guidance for its eye drug Macugen prior to its fourth-quarter and ... TheStreet.com - TheStreet.com (subscription) Differing Views On OSI's Macugen - Aug 8, 2006 Two Wall Street analysts had opposing views on shares of OSI Pharmaceuticals after the company reported second-quarter results and disappointing sales for ... Forbes Eyetech Raises Macugen Estimate - Jun 22, 2005 Eyetech(EYET Quote) sharply raised its 2005 sales estimate for eye-disease treatment Macugen on Wednesday, saying the drug is proving more popular than ... TheStreet.com - TheStreet.com (subscription) … Pharma says interim phase II results of Macugen trials 'suggest... - Jun 1, 2006 LONDON (AFX) - OSI Pharmaceuticals Inc said results from an interim phase II study of its Macugen drug, which it co-develops and co-promotes in the US with ... Forbes OSI Pharma Weighed Down By 'Macugen Baggage' - Aug 29, 2005 Credit Suisse First Boston lowered the price target and updated estimates for OSI Pharmaceuticals (nasdaq: OSIP - news - people ) in light of the company's ... Forbes Condemned to blindness: Scots get drug that can save sight, but... - Jun 14, 2007 Nice rejected the use of Macugen for patients with the most common form of ... Macugen and Lucentis, known as anti- VEGF drugs, stop the deterioration of ... Daily Mail Rare Reactions Reported With Macugen - Apr 10, 2006 Pfizer Pharmaceuticals, (OSI) Eyetech Inc., and the FDA are alerting health care professionals to risks associated with injections of Macugen, a medication ... WebMD OSI Shares Fall as Investors Question Deal - Aug 23, 2005 Ms. Lu said Eyetech's main product, Macugen, would lose market share in 2007, ... Eyetech, based in New York, introduced Macugen in January with its partner ... New York Times Ex-MP battles NHS over eye drug - Jan 30, 2007 Two of the treatments only help a small percentage of patients, but two new drugs, Macugen and Lucentis, are suitable for most patients. ... BBC News Thousands losing sight in NHS postcode lottery - May 22, 2007 Even those doctors who can get the drugs, sold as Lucentis and Macugen, ... Lucentis, Macugen and Avastin are known as anti-vegf treatments because they ... Telegraph.co.uk California; Eye Drug Shows Promise, Genentech Says - May 24, 2005 Lucentis would compete with Macugen, a drug from Eyetech Pharmaceuticals Inc. ... The Macugen product label says that, on average, patients on Macugen lost ... Pay-Per-View - Los Angeles Times - ProQuest Archiver OSI's Macugen Still Burdened By Lucentis Threat - May 10, 2006 Wachovia Securities reiterated an "underperform" rating on OSI Pharmaceuticals after the company reported mixed results for the first quarter late Monday. ... Forbes OSI Shares Hammered Over Eyetech Price - Aug 22, 2005 Lu said Eyetech's main product Macugen will lose market share in 2007 and show ... Eyetech partnered with Pfizer (PFE) to launch Macugen as a treatment for ... FOXNews Eye patients 'at greater heart attack risk' - Feb 28, 2008 Treatments for wet AMD, such as Lucentis, Macugen and Avastin, are known as anti-VEGF treatments because they prevent the growth of blood vessels by ... Telegraph.co.uk 'U-turn' over sight-saving drugs - Dec 14, 2007 But a second drug, Macugen, is still not recommended for use on the NHS. ... Both Macugen and Lucentis are from a class known as anti-VEGF drugs, ... BBC News Mixed Results for OSI - May 9, 2006 US Macugen sales were $51 million during the quarter. The most recent quarter was the first time Macugen was included in OSI's overall sales. ... TheStreet.com - TheStreet.com (subscription) Genentech News Slices Small Rival's Stock; Eyetech plunges 46% as … - May 25, 2005 In previous studies, Eyetech's Macugen drug improved or maintained vision in 70% ... And Eyetech CEO David Guyer said Macugen was being tested on other eye ... Pay-Per-View - Los Angeles Times - ProQuest Archiver A caring eye for detail - Mar 4, 2008 The SMC followed on from its earlier positive recommendation on Macugen when it announced its decision to recommend Lucentis. This was in June 2007, ... Scotsman Watchdog to review its restrictions on blindness drugs - Aug 9, 2007 A meeting scheduled for tomorrow on the guidance, which relates to the drugs Lucentis and Macugen, has been postponed while the cost is assessed. ... guardian.co.uk More Eye-Opening Data From Genentech - Jul 18, 2005 Aside from Macugen, Visudyne, from Novartis (nyse: NVS - news - people ) and ... It's not clear whether any conclusions can be drawn comparing Macugen to ... Forbes 20,000 'may go blind' after being denied sight-saving drug available... - Aug 7, 2006 Macugen is designed to combat the wet form of age-related macular degeneration ... 'Patients' inability to obtain Macugen means that as many as 20000 people ... Daily Mail Charity to fund sight-drug fight - Jul 9, 2007 Macugen costs about £10000 a year, and Lucentis about £12000. Both drugs have been made widely available in Scotland. ... BBC News Genentech in Competition With Itself on Eye Drug - Sep 27, 2005 That is much less than the cost of Macugen, a drug already approved for macular degeneration that is sold by Pfizer and Eyetech Pharmaceuticals, ... New York Times Macugen can boost visual acuity - May 30, 2008 Macugen can maintain or improve visual acuity in patients with neovacular age-related macular degeneration, according to a study presented at the recent ... Optician Online Patients denied 'blindness' drug - Oct 27, 2006 A drug called Macugen was licensed in May this year for the treatment of wet age-related ... Macugen targets VEGF (vascular endothelial growth factor), ... BBC News Earnings Miss Hits Eyetech | Biotech/Pharmaceuticals | Financial... - Feb 16, 2005 Eyetech recently began selling Macugen, a drug designed to treat the ... Eyetech began selling Macugen Jan. 20; the Food and Drug Administration approved ... TheStreet.com - TheStreet.com (subscription) … European Regulatory Approval for Macugen(R) (Pegaptanib Sodium … - Feb 2, 2006 Macugen has been proven to prevent and reduce vision loss in patients with ... "More than 50000 patients have been treated with Macugen in the United States ... RedOrbit NICE dismisses Macugen appeal - Sep 12, 2008 The Royal College of Ophthalmologists (RCO) has hit out at the National Institute for Health and Clinical Excellence (NICE) for its decision to dismiss an ... Optician Online NICE was wrong to ration sight-saving drug, claim doctors - Jul 3, 2007 Last month, NICE said Macugen, also known as pegaptanib, should not be given ... Macugen costs £514 for each injection or £4630 for nine injections a year. ... Daily Mail Eyetech's Macugen Seen Losing Share To Lucentis - Nov 1, 2005 Standard & Poor's Equity Research analyst Phillip Seligman maintained a "hold" rating on Eyetech Pharmaceuticals (nasdaq: EYET - news - people ) after the ... Forbes OSI Pharmaceuticals Summarizes Macugen(R) (pegaptanib sodium … - May 4, 2006 NEW YORK -- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) today provided an informational update summarizing highlights from presentations made regarding ... Free with registration - Business Wire - AccessMyLibrary.com Few Focus on Eyetech | Robert Steyer News | Print Financial &... - Jun 29, 2005 Although Eyetech's shares had been fading since the beginning of the year when the company and Pfizer (PFE Quote) began marketing Macugen, the Genentech ... TheStreet.com - TheStreet.com (subscription) Melville, NY, pharmaceutical company vows more shareholder input. - Feb 7, 2006 OSI recently acquired Manhattan-based Eyetech Pharmaceuticals, the maker of Macugen, a vision-loss drug. The deal stalled amid objections that OSI was ... Free with registration - Newsday - AccessMyLibrary.com (From Western Daily Press) - Feb 9, 2007 Macugen has already been used very successfully in America and Scotland, ... A specialist at Musgrove Park Hospital, Taunton, told him that Macugen would be ... Free with registration - Europe Intelligence Wire - AccessMyLibrary.com … and Pfizer Announce Phase IV Macugen(R)(Pegaptanib Sodium … - Jun 26, 2006 OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) and Pfizer Inc. (NYSE: PFE) today announced the initiation of LEVEL (EvaLuation of Efficacy and safety in ... RedOrbit Event Brief of Q4 2006 OSI Pharmaceuticals, Inc. Earnings Conference ... - Feb 21, 2007 Included was a charge relating to the impairment of Macugen intangibles. 1. ... Due to the uncertainty surrounding future sales levels of Macugen, ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Liverpool News New drugs help for eye patients - Jan 29, 2008 Macugen and Lucentis do not work for everyone, as sometimes the damage is too ... We also support the decision to make both Lucentis and Macugen available, ... Liverpool Daily Post OSI, Eyetech merger delayed over drug concerns. - Nov 10, 2005 Both Macugen and Lucentis are used to treat age-related macular ... Macugen, which is co-marketed by Pfizer Inc. , is Eyetech's primary revenue driver. ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Macular degeneration - Aug 14, 2006 Macugen. Pegaptanib (Macugen) is approved for the treatment of wet macular ... Like Macugen, ranibizumab (Lucentis) is an anti-VEGF drug used to treat wet ... cnn.com Shots in the eye curb diabetic loss of sight, Drug tests show... - Jan 9, 2007 The data suggest, he said, that injections of the Eyetech drug Macugen tend to reverse new blood- vessel growth in patients with diabetic retinopathy. ... Pay-Per-View - Newsday - ProQuest Archiver Treatment of Early Disease With Macugen (Pegaptanib Sodium Injection)... - Oct 5, 2005 NEW YORK, NY -- October 5, 2005 -- Eyetech Pharmaceuticals, Inc. and Pfizer Inc announced today that exploratory analyses of the VISION (VEGF Inhibition ... DG News OccuLogix Crushed After Rheo Trial - Feb 3, 2006 OSI Pharmaceuticals (OSIP:Nasdaq) also has a wet AMD drug, called Macugen, that it inherited when it acquired Eyetech Pharmaceuticals. ... TheStreet.com - TheStreet.com (subscription) Macugen(R) (Pegaptanib Sodium Injection) Receives Positive Opinion... - Sep 16, 2005 NEW YORK, Sept. 16 /PRNewswire-FirstCall/ -- Eyetech Pharmaceuticals, Inc. announced today that the Committee for Medicinal Products for Human Use (CHMP), ... RedOrbit RNIB's blind fury over Nice delays - Aug 13, 2007 Only those patients who had already gone blind in one eye would be eligible for anti-VEGF drugs Macugen and Lucentis. An unprecedented 20000 people and ... WalesOnline Genentech's Lucentis Cleared - Jun 30, 2006 Another option for treating AMD is Macugen, a drug sold by OSI Pharmaceuticals ... OSI inherited Macugen when it acquired Eyetech Pharmaceuticals last year. TheStreet.com - TheStreet.com (subscription) … Timing of European Union Approval for Macugen(R)(Pegaptanib Sodium... - Dec 14, 2005 OSI now anticipates European Union approval of Macugen in January 2006 and ... Macugen was approved by the US Food and Drug Administration in December 2004 ... RedOrbit Pegaptanib Injection Shows Promising Results in Diabetic Macular … - May 6, 2005 These new preliminary observations from the Macugen Phase 2 DME trial were presented at ... Macugen is indicated in the United States for the treatment of ... RxPG NEWS OSI Pharmaceuticals Completes Its Acquisition of Eyetech … - Nov 14, 2005 We now have two major market products in Tarceva and Macugen and a robust ... We believe that Tarceva and Macugen are two of the most exciting and novel ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com GM Falls on Fitch Debt Downgrade - May 24, 2005 Shares of Pfizer (PFE ), Eyetech's marketing partner for Macugen, were also lower. The MidAmerican Energy Holdings unit of Warren Buffett's Berkshire ... BusinessWeek Lucentis Application Set for Year-End - Sep 7, 2005 Macugen has been shown to decrease vision loss, but after Genentech released its preliminary Lucentis data a few months ago, shares of Eyetech sank. ... TheStreet.com - TheStreet.com (subscription) Macugen granted US marketing approval for wet AMD treatment - Feb 1, 2005 Eyetech is working on a longer-lasting formulation. The drug is also being investigated for treatment of diabetic macular edema and other retinal vascular ... OSN SuperSite We face sacrificing our home to save our eyesight - Jun 17, 2007 Lawrence, 74, and Joan, 70, are paying out for treatments of Avastin, which is cheaper than Lucentis and other anti-blindness drug Macugen. ... Southern Daily Echo OSI looks to unload Macugen, exit eye diseases - Nov 6, 2006 Just a year after buying Macugen from Eyetech (a 2003 Fierce 15 company), OSI Pharmaceuticals is looking for a way out of the eye disease sector. ... FierceBiotech Genentech's Peer Premium Seen Well Justified - Jan 17, 2006 Lucentis is also seen as a potential competitor to Macugen, a treatment markted by OSI Pharmaceuticals (nasdaq: OSIP - news - people ) and Pfizer (nyse: PFE ... Forbes Event Brief of Q4 2005 OSI Pharmaceuticals, Inc. Earnings Conference ... - Mar 8, 2006 OSIP records all US sales of Macugen. 2. The Co. reports sales net of returns ... The Co. believes one way to look at and compare US results for Macugen and ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Systemic Safety Profile of Macugen(R) (Pegaptanib Sodium Injection) … - Feb 24, 2006 OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) and Pfizer Inc (NYSE: PFE) announced today that the systemic safety profile of Macugen(R) (pegaptanib sodium ... RedOrbit QLT Puts Self Up for Sale as Shares Languish Near Low - Nov 28, 2007 Last year, QLT cut 80 jobs because of competition to Visudyne from Genentech Inc.'s Lucentis and Pfizer Inc.'s Macugen. QLT works with Sanofi-Aventis SA to ... Bloomberg … Analyses Suggest That Treatment With Macugen(R) (pegaptanib sodium... - May 10, 2005 NEW YORK, Oct. 5 /PRNewswire-FirstCall/ -- Eyetech Pharmaceuticals, Inc. and Pfizer Inc announced today that exploratory analyses of the VISION (VEGF ... Euro am Sonntag … Pharmaceuticals, Inc. US FDA approves Macugen for treatment of … - Jan 19, 2005 2005 JAN 19 - (NewsRx.com & NewsRx.net) -- Eyetech Pharmaceuticals, Inc., (EYET) and Pfizer, Inc., (PFE) announced that the US Food and Drug Administration ... Pay-Per-View - Biotech Week - Factiva, from Dow Jones Studies Show Macugen (pegaptanib) Effective in Treating Age-Related … - Jan 18, 2005 By Larry Schuster, MedPage Today Staff Writer. In recent years, extensive evidence has suggested that vascular endothelial growth factor (VEGF) plays a ... MedPage Today Companies eye slice of age-related macular degeneration market - Sep 1, 2006 Indeed, Lucentis' arrival on the market will be a major blow to Macugen, ... Macugen is effective but not as effective as Lucentis," says Tony Adamis, ... Nature.com Safety Profile of Macugen(R) (pegaptanib sodium injection) in the … - May 2, 2005 NEW YORK, May 2 /PRNewswire-FirstCall/ -- Eyetech Pharmaceuticals, Inc. announced today that the proven safety profile of Macugen(R) (pegaptanib sodium ... $4.95 - PR Newswire - ECNext … Raises Full-Year Sales Forecast for Macugen(R) (pegaptanib sodium ... - Jun 22, 2005 NEW YORK, June 22 /PRNewswire-FirstCall/ -- Eyetech Pharmaceuticals, Inc. announced today that it revised its 2005 forward-looking guidance for net product ... $4.95 - PR Newswire - ECNext Clear vision for Macugen: the marketers of Macugen, the second drug... - Mar 1, 2005 The success of Macugen will partly depend on whether doctors and patients accept a product that must be administered by injection in the eye about 18 times ... Pay-Per-View - Med Ad News - Factiva, from Dow Jones Macugen to enter phase 4 trials - Jun 29, 2006 NEW YORK — An intravitreal injection for the treatment of age-related macular degeneration will enter a phase 4 maintenance trial, the drug's marketers said ... OSN SuperSite Is Eyetech Better Than It Looks? - May 31, 2005 Investors, hungry for a stake in Eyetech's Macugen, the company's novel ... That top line response rate is better than anything out of the Macugen trials. ... fool.com European Commission grants Macugen regulatory approval - Mar 15, 2006 The drug must go through reimbursement approvals for each EU country before it can be launched. by Jared Schultz. The European Commission has granted ... OSN SuperSite Macugen reimbursement terms announced - Feb 8, 2005 NEW YORK — The Centers for Medicare & Medicaid Services announced a reimbursement level for a recently approved drug for age-related macular degeneration. ... OSN SuperSite … Patient in a Phase 3 Clinical Trial of Macugen(R) (Pegaptanib... - Oct 17, 2005 Macugen is indicated in the United States for the treatment of ... "In limited Phase 2 studies, Macugen, the only anti-VEGF therapy being studied in DME and ... RedOrbit Thousands denied eye drug over NHS costs - May 18, 2006 Macugen, a new treatment for age-related macular degeneration, ... But Macugen has not yet been cleared by NICE, the National Institute for Health and ... Times Online … to quit eye care, but will continue to support Macugen.(New... - Dec 15, 2006 OSI Pharmaceuticals announced that it is leaving the eye disease business. Last year, the company acquired Eyetech and its flagship drug Macugen (pegaptanib ... Free with registration - Review of Optometry - AccessMyLibrary.com … Macular Degeneration; US FDA approves Macugen for treatment of … - Jan 23, 2005 2005 JAN 23 - (NewsRx.com & NewsRx.net) -- Eyetech Pharmaceuticals, Inc., (EYET) and Pfizer, Inc., (PFE) announced that the US Food and Drug Administration ... Pay-Per-View - Medical Letter on the CDC & FDA - Factiva, from Dow Jones … due $90M as FDA clears Macugen.(Eyetech Pharmaceuticals)(Food and ... - Jan 3, 2005 Eyetech Pharmaceuticals and Pfizer's Macugen (pegaptanib sodium injection), the first in a new class of ophthalmic drugs to specifically target vascular ... Free with registration - Pharma Marketletter - AccessMyLibrary.com … ; Systemic safety profile of Macugen in macular degeneration... - Mar 28, 2006 2006 MAR 28 - (NewsRx.com) -- OSI Pharmaceuticals, Inc. (OSIP) and Pfizer Inc (PFE) announced that the systemic safety profile of Macugen (pegaptanib sodium ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones Press Release: Macugen(R) (pegaptanib sodium injection) Receives … - Sep 16, 2005 Macugen(R) (pegaptanib sodium injection) Receives Positive Opinion for Treatment of Neovascular Age-Related Macular Degeneration from the European Medicines ... Pay-Per-View - PR Newswire - HighBeam Research Nathan's is really cookin': Hot dog! says Westbury food giant,... - Aug 8, 2006 Company officials said the increase was largely due to growth in Tarceva sales and the addition of Macugen-related revenue streams. ... Free with registration - Newsday - AccessMyLibrary.com International Approvals: Diovan, Velcade, Macugen - May 16, 2005 May 16, 2005 — The European Commission has approved new indications for valsartan tablets and bortezomib for injection, allowing their use to reduce the ... Medscape Press Release: Safety Profile of Macugen(R) (pegaptanib sodium … - May 2, 2005 Safety Profile of Macugen(R) (pegaptanib sodium injection) in the Treatment of Neovascular Age-Related Macular Degeneration (AMD) Maintained For Two Years. Pay-Per-View - PR Newswire - HighBeam Research Press Release: Eyetech Announces Approval of Macugen(R) in Brazil for... - May 24, 2005 Eyetech Announces Approval of Macugen(R) in Brazil for the Treatment of Neovascular (Wet) Age-Related Macular Degeneration. from PR Newswire. Pay-Per-View - PR Newswire - HighBeam Research … Differences between Intravitreal Macugen and IV Triamcinolone: … - May 14, 2007 Macugen was administered every 6 weeks and PDT could be repeated if retinal leakage was ... All percentages (PDT/Macugen 73.7%; PDT/triamcinolone 81.3%; ... DG News … : Eyetech Announces Launch Date for Macugen(R) (pegaptanib sodium … - Jan 20, 2005 Eyetech Announces Launch Date for Macugen(R) (pegaptanib sodium injection). from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research Macugen shows benefit through second year of treatment for AMD - Jul 21, 2005 MONTREAL — Two years of treatment with pegaptanib provided sustained benefit for patients with age-related macular degeneration, according to a physician ... OSN SuperSite … , Inc. Announces Reimbursement Terms for Macugen(R). - PR Newswire... - Feb 7, 2005 Macugen was approved by the FDA on December 17, 2004 for use in the treatment of neovascular ... Eyetech and Pfizer launched Macugen on January 20, 2005. ... Pay-Per-View - PR Newswire - HighBeam Research OSI Pharmaceuticals R&D Day - Part 3. - Mar 10, 2006 After 36 weeks of Macugen therapy, the neovascularization has completely regressed, ... Here is one anecdotal case, patient 2400, treated with Macugen, ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com … Release: European Commission Approves Macugen for Treatment of All... - Feb 2, 2006 European Commission Approves Macugen for Treatment of All Types of Wet Age-Related Macular Degeneration; First Treatment to Target Underlying Disease ... Pay-Per-View - PR Newswire - HighBeam Research … and Pfizer Announce FDA Approval of Macugen for the Treatment of … - Jan 7, 2005 Macugen helps preserve vision and helps limit progression to legal blindness. Macugen is the first in a new class of ophthalmic drugs to specifically target ... businesswire.com Eyetech Announces Approval of Macugen(R) in Brazil for the Treatment... - May 24, 2005 NEW YORK, May 24 /PRNewswire-FirstCall/ -- Eyetech Pharmaceuticals, Inc. announced today that Brazil's National Health Surveillance Agency (Agencia Nacional ... $4.95 - PR Newswire - ECNext Macugen(R) (pegaptanib sodium injection) Named Innovative … - Aug 9, 2005 Macugen is the first and only FDA-approved treatment for all types of neovascular ... Macugen is also the first in a new class of drugs called aptamers, ... $4.95 - PR Newswire - ECNext Pfizer to initiate QoL study of Macugen.(Brief Article) - Oct 24, 2005 World drugs giant Pfizer says that it will conduct a clinical study, using quality-of-life parameters relevent to the visually impaired, of its drug Macugen ... $4.95 - Pharma Marketletter - ECNext GENENTECH SEEKS OK FOR VISION TREATMENT - Dec 31, 2005 Genentech filed for US approval of the vision treatment Lucentis, which would compete with OSI Pharmaceuticals' Macugen as a treatment for macular ... $2.95 - San Jose Mercury News - NewsBank DRUGS MAY HELP WITH MACULAR DEGENERATION - Oct 13, 2006 Three relatively new drugs - Lucentis, Macugen and Avastin - all attack VEGF, ... Macugen was approved for the wet disease two years ago, but appears to be ... Pay-Per-View - The Sun - ProQuest Archiver Eyetech Reiterates Confidence in Macugen(R) (pegaptanib sodium … - May 28, 2005 Eyetech Pharmaceuticals, Inc. (Nasdaq: EYET) announced that it will hold a conference call to reiterate its confidence in Macugen and discuss issues ... Medical News Today - Medical News Today (press release) OSI Pharmaceuticals Announces Second Quarter 2006 Financial Results. - Aug 7, 2006 Total US Macugen sales were $36.7 million and $87.2 million for the three and six ... In response to declining Macugen revenues and developments in the AMD ... Free with registration - Business Wire - AccessMyLibrary.com Finance; Drug Royalty USA, Inc. shares royalty rights in Macugen - Jan 18, 2005 2005 JAN 18 - (NewsRx.com & NewsRx.net) -- Isis Pharmaceuticals, Inc. has sold a portion of its royalty rights in Macugen (pegaptanib sodium injection) to ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones Eyetech/Pfizer's Macugen: better in early disease.(Eyetech … - Oct 17, 2005 The USA's Eyetech Pharmaceuticals and drugs giant Pfizer say that their co-developed Macugen (pegaptanib sodium) injection 0.3mg may further reduce the risk ... Pay-Per-View - Pharma Marketletter - Factiva, from Dow Jones Pfizer's $527M Angiosyn Bid Not A Challenge To Macugen - Jan 25, 2005 By Randall Osborne. Building upon its ophthalmology franchise, Pfizer Inc. entered an agreement with Angiosyn Inc. to buy the privately held start-up for an ... BioWorld Online - BioWorld Online Article: The FDA approved Macugen (pegaptanib sodium injection) 0.3 … - Feb 1, 2005 The FDA approved Macugen (pegaptanib sodium injection) 0.3 mg, for the treatment of neovascular (wet) age-related macular degeneration. Pay-Per-View - Medical Marketing & Media - HighBeam Research … , Inc. Drug Royalty USA, Inc. shares royalty rights in Macugen - Jan 19, 2005 Under the terms of the agreement, Isis and DRC will share the royalty rights on Macugen through 2009. After 2009, Isis retains all royalties to Macugen. ... Pay-Per-View - Biotech Week - Factiva, from Dow Jones Eyetech Reports Third Quarter 2005 Financial Results. - Oct 31, 2005 Net product revenue for Macugen was $55.5 million, an 18% increase over the previous ... "Macugen continued to capture an increasing share of a growing ... $4.95 - PR Newswire - ECNext |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |
